Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Audrey Simonaggio

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Future Oncology (London, England)|January 19, 2021
Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a reviewCedric Pobel, Edouard Auclin, Adrien Procureur, et al.
Bulletin Du Cancer|July 5, 2020
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancerNicolas Epaillard, Audrey Simonaggio, Reza Elaidi, et al.
Annals of Intensive Care|October 16, 2020
Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unitAdrien Joseph, Audrey Simonaggio, Annabelle Stoclin, et al.
JAMA Oncology|June 7, 2019
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With CancerAudrey Simonaggio, Jean Marie Michot, Anne Laure Voisin, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical studyJean-Marie Michot, Ariane Lappara, Jérôme Le Pavec, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Future Oncology (London, England)|January 19, 2021
Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a reviewCedric Pobel, Edouard Auclin, Adrien Procureur, et al.
Bulletin Du Cancer|July 5, 2020
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancerNicolas Epaillard, Audrey Simonaggio, Reza Elaidi, et al.
Annals of Intensive Care|October 16, 2020
Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unitAdrien Joseph, Audrey Simonaggio, Annabelle Stoclin, et al.
JAMA Oncology|June 7, 2019
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With CancerAudrey Simonaggio, Jean Marie Michot, Anne Laure Voisin, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical studyJean-Marie Michot, Ariane Lappara, Jérôme Le Pavec, et al.
Pageof 2